Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.
The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.
The European-based survey collected information from over 900 patients and caregivers from 25 countries; the responses show a need for both local and national governments to scale up their services for patients with rare metabolic diseases, which also have a positive spillover effects for caregivers.
Survey responses from patients with advanced cancer revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including about side effects and curative potential.
Researchers found the 3 treatments—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel (liso-cel)—showed promising efficacy and safety results across histological types, although they noted a need for more real-world data to validate the efficacy of liso-cel.
The researchers of a new analysis argue that the treatments they investigated for acute myelogenous leukemia (AML) are worthy of clinical promotion based on their findings, which they say also provide evidence-based guidance for clinical practice.
The findings come from a pooled analysis of the ELIANA and ENSIGN trials, both of which led to the approval of tisagenlecleucel for these patients.
Few cases have documented how myeloproliferative neoplasms, such as polycythemia vera, progress to pure erythroid leukemia, with just 5 such cases reported between 1952 and 1962.
The combination delayed disease progression for a year and a half, suggesting the treatments may be a viable option for patients not eligible for allogeneic stem cell transplantation.
Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.
In a preclinical study, researchers were able to show that their modified adeno-associated virus (AAV) vector safely delivered the chimeric antigen receptor (CAR) gene into the host cells and produced enough CAR T cells to cause effective tumor regression and elicit antitumor immunological characteristics in a mouse model of human T-cell leukemia.
Due to the lack of head-to-head trials comparing chemoimmunotherapy regimens with chemotherapy alone as first-line treatment for non-small cell lung cancer, researchers conducted a network meta-analysis of 17 randomized controlled trials of patients with the cancer.
Using a systems biology approach, the researchers discovered 64 genes shared between non-alcoholic fatty liver disease (NAFLD) and hypertension, considered to be core genes for the 2 conditions.
Clostridioides difficile, a bacteria that creates inflammation of the colon and causes symptoms like infectious diarrhea, is of particular risk among hospitalized patients.
The analysis included 64 cost-effectiveness analysis scenarios across more than 30 studies between 2009 and 2019, approximately half (53%) of which determined precision diagnostic testing to be cost-effective.
The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in these patients.
According to researchers, the prevalence of progressive supranuclear palsy (PSP) identified by their study is consistent with, but on the lower end, of previously reported estimates.
In a recent review article, a researcher outlined current guidance for the management of patients with chronic lymphocytic leukemia (CLL) as the pandemic continues throughout the country.
The study included more than 400 patients with Philadelphia-negative MPNs, all of whom completed a questionnaire related to their tobacco use and symptoms related to their disease.
Understanding of precision oncology has grown among patients, according to the researchers, who explained that in 2012, less than 50% of surveyed patients knew what “precision oncology” meant.
Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).
Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).
A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.
Researchers have found that the number of variants a patient had in their plasma had prognosis implications, with circulating cell-free DNA mutational load having a significant association with overall survival.
The researchers identified 3 immune subtypes of esophageal cancer (EC) among the samples, all of which had different prognostic implications.
Although there is hope chimeric antigen receptor (CAR) T-cell therapy can revolutionize how to treat glioblastoma multiforme (GBM), there is still more research to be done, say investigators, noting that research on CAR T-cell therapy in this setting is still in early stages.
